Carvedilol Versus Placebo for Treatment in Post Traumatic Stress Disorder (PTSD)

Status unconfirmed · Phase 2 · Has a placebo group

Conditions studied: Post-Traumatic Stress Disorder

In brief

The investigators hypothesize that carvedilol, at less then therapeutic doses for cardiac effect, will reduce symptoms of Post Traumatic Stress Disorder.

Key facts

Study ID

NCT01221792

Run by

Columbia Northwest Pharmaceuticals

People needed

80

Starts

2010-10-01

Expected to finish

2011-08-01

Last updated by the study team

2011-06-08

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Post Traumatic Stress Disorder according to DSM-IV
• Must be able to speak, read and understand the English language and be able to provide written informed consent

You may not qualify if…

• current, unstable and significant medical condition/illness
• bronchial asthma or related bronchospastic condition
• AV block
• Sick Sinus Syndrome
• Bradycardia
• Peripheral hear disease
• Unstable thyroid disorder
• History of seizure disorder
• Females who are pregnant, lactating or planning to become pregnant
• Bipolar
• Schizophrenia
• Dementia
• Intolerance or hypersensitivity to alpha or beta blockers

Where it is running

• Artemis Institute for Clinical Research — San Diego, California, United States
• Lake Charles Clinical Trials — Lake Charles, Louisiana, United States
• Northwest Clinical Research Center — Bellevue, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.